418 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AZN Astrazeneca PLC $37.56 $95.16B Downtrend
Article Searches
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales http://www.zacks.com/stock/news/354603/astrazenecas-azn-q4-earnings-beat-new-drugs-drive-sales?cid=CS-ZC-FT-354603 Feb 14, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs http://www.zacks.com/stock/news/353203/pharma-stock-roundup-q4-earnings-at-mrk-lly-chmp-nod-for-several-drugs?cid=CS-ZC-FT-353203 Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Why Astrazeneca (AZN) Could Beat Earnings Estimates Again http://www.zacks.com/stock/news/351870/why-astrazeneca-azn-could-beat-earnings-estimates-again?cid=CS-ZC-FT-351870 Feb 04, 2019 - Astrazeneca (AZN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY http://www.zacks.com/stock/news/348355/pharma-stock-roundup-regulatory-updates-in-focus-at-pfe-bmy-rhhby-sny?cid=CS-ZC-FT-348355 Jan 18, 2019 - Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.
Immunomedics Gets CRL From FDA for Breast Cancer Candidate http://www.zacks.com/stock/news/348241/immunomedics-gets-crl-from-fda-for-breast-cancer-candidate?cid=CS-ZC-FT-348241 Jan 18, 2019 - Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.
NVS or AZN: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/348018/nvs-or-azn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-348018 Jan 17, 2019 - NVS vs. AZN: Which Stock Is the Better Value Option?
Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C http://www.zacks.com/stock/news/347742/ironwoods-irwd-linzess-gets-approval-in-china-for-ibs-c?cid=CS-ZC-FT-347742 Jan 16, 2019 - Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C
What's in Store for Merck in 2019 After a Solid Run in '18? http://www.zacks.com/stock/news/347164/whats-in-store-for-merck-in-2019-after-a-solid-run-in-18?cid=CS-ZC-FT-347164 Jan 14, 2019 - Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff http://www.zacks.com/stock/news/346023/ironwood-to-get-new-ceo-current-ceo-to-head-latest-spinoff?cid=CS-ZC-FT-346023 Jan 07, 2019 - Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.
Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate http://www.zacks.com/stock/news/345809/pharma-stock-roundup-bmy-to-buy-celg-for-%2474b-mrk-gets-rights-to-nash-candidate?cid=CS-ZC-FT-345809 Jan 04, 2019 - Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.

Pages: 12345678910...42

<<<Page 5>